secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001437749-23-013597
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AcelRx Q1 net loss $8.2M; DSUVIA divestiture closed, Niyad EUA submitted
------------------------------------------------------------------------

- Net loss $8.2M ($0.75/share) vs $8.7M loss in Q1 2022; cash $13.4M at March 31, 2023.
- DSUVIA divestiture to Alora closed April 3; 15% royalty on commercial sales, 75% on DoD, up to $116.5M milestones.
- EUA request for Niyad (nafamostat mesylate) submitted to FDA April 27; registrational study expected H2 2023.
- Combined R&D and SG&A expenses $5.3M, up from $4.9M, driven by legal and Niyad costs.
- Recognized $7.0M impairment on net assets held for sale from DSUVIA discontinued operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774923013597/0001437749-23-013597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774923013597/acrx20230509_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-013597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer